Good
Mostly Aligned
Patient Risk:
Low
Summary
Most medical/label-relevant statements about composition and dosing frequency align with the provided FDA label excerpts. However, some claims are either broader than the label excerpts (asthma age limitation not mentioned) or are not supported by the provided prescribing information (pricing and savings programs).
Category Scores
Accurate Statements
Trelegy Ellipta is a combination inhaler used to treat COPD and asthma.
Section 1.1 indicates COPD maintenance treatment; Section 1.2 indicates asthma maintenance treatment in patients aged 18 years and older.
Trelegy Ellipta contains fluticasone furoate, umeclidinium, and vilanterol.
Sections 12.1 and the composition shown in the provided label excerpts (active ingredients list and dose strengths) state the fixed-dose combination of fluticasone furoate, umeclidinium, and vilanterol.
Trelegy Ellipta is typically prescribed as one inhalation once daily.
Section 2.1: administer 1 actuation once daily; Section 2.2/2.3: recommended dosage is 1 actuation once daily.
A single inhaler is designed to last for one month.
Not explicitly supported by the provided label excerpts.
Unsupported Statements
Without insurance, the retail price of Trelegy Ellipta can be several hundred dollars for a 30-day supply.
Pricing and insurance-cost statements are not supported by the provided prescribing information excerpts.
One source indicates a price around $580 for a single inhaler of Trelegy Ellipta.
Price figures are not supported by the provided prescribing information excerpts.
The manufacturer (GSK) offers a Trelegy Ellipta Savings Program for eligible commercially insured patients.
Patient savings/program availability is not supported by the provided prescribing information excerpts.
The Trelegy Ellipta Savings Program can reduce out-of-pocket costs.
Program benefit/out-of-pocket reduction is not supported by the provided prescribing information excerpts.
Patient assistance programs may be available for those who qualify based on income and insurance status.
Patient assistance availability and eligibility criteria are not supported by the provided prescribing information excerpts.
Trelegy Ellipta is priced comparably to other advanced, multi-component inhalers for managing COPD and asthma.
Comparative pricing claims are not supported by the provided prescribing information excerpts.
Prices for inhalers in this class can range from under $100 to over $500 per month depending on the specific drug, formulation, and insurance plan.
Class pricing range claims are not supported by the provided prescribing information excerpts.
Contradictions
Important Omissions
Asthma indication is limited in the provided excerpt to patients aged 18 years and older; the claim did not mention this age limitation.
Importance:
Moderate
Dosage/administration instructions include rinsing the mouth with water after inhalation without swallowing and not using more than 1 time every 24 hours; the claim only stated 'once daily' and did not include these administration instructions.
Importance:
Moderate
The FDA excerpt states TRELEGY ELLIPTA is not indicated for relief of acute bronchospasm and should not be used as rescue therapy for acute episodes; none of the provided claims addressed this limitation.
Importance:
Moderate
The 'one inhaler is designed to last for one month' statement is not supported by the provided prescribing information excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label-relevant medication details (fixed-dose combination; once-daily actuation) are largely consistent with the provided excerpts. Main issues are unsupported non-label pricing/program claims and omission of the asthma age limitation and rescue/acute symptom limitation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Non-label claims (pricing and savings/assistance programs) are not supported by the provided FDA prescribing information, and key label limitations/administration details were omitted (asthma age ≥18; not for rescue/acute bronchospasm).
Suggested Improvement
Restrict statements to label-supported content in Sections 1 and 2 (e.g., maintenance indications, asthma age cutoff, once-daily 1 actuation, not a rescue therapy, and post-inhalation mouth rinse). Remove or clearly separate pricing and program information since it is not present in the provided prescribing information excerpts.